295 MADISON AVENUE, NEW YORK, NY
Receives regulatory approval to sell the Transdermal GFR System in China
Portfolio Company to Pay Cash Dividend
R2 has Explosive Growth and Global Reach with Glacial® Skin Continuing to Redefine Aesthetic Innovation
Announces Second Quarter 2025 Results
Closes Indebtedness Refinancing Transactions
Announces Early Results of Exchange Offer of Senior Secured Notes and Solicitation of Consents and Extends Availability of Total Early Exchange Consideration
Launches Indebtedness Refinancing Transactions
Q2
Q1
FY 2024
Q3
FY 2023
Notice of Exempt Offering of Securities
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Definitive Information Statement
PRE 14A
Amended Statement of Changes in Beneficial Ownership
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload